A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
From MaRDI portal
Publication:6622241
DOI10.1002/SIM.9242zbMATH Open1545.62473MaRDI QIDQ6622241
Rui Tang, Jin Xu, Rongji Mu, Ying Yuan, Scott Kopetz
Publication date: 22 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
Cites Work
- Title not available (Why is that?)
- Title not available (Why is that?)
- Title not available (Why is that?)
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- A weakly informative default prior distribution for logistic and other regression models
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- A Bayesian Phase I/II Trial Design for Immunotherapy
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- Bayesian Analysis of Binary and Polychotomous Response Data
- Dose-Finding Based on Multiple Toxicities in a Soft Tissue Sarcoma Trial
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
- gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
- A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point
This page was built for publication: A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6622241)
